

## Special Issue

# Synthesis of Heterocyclic Compounds with Antitumor Properties

### Message from the Guest Editors

Cancer represents the second leading cause of death worldwide. To date, drug treatment together with surgical operation, radiotherapy, and chemotherapy constitute the main approaches to cancer treatment. Small molecules with heterocyclic scaffold are widely used to treat a variety of cancers with small molecules and show great diversity in their action mechanisms. Over the past two decades, there has been a huge shift in cancer treatment, leading to targeted drugs; nevertheless, this significant progress in treatment is still not very specific or effective. Therefore, we are currently facing numerous difficulties relating to the search for progress in cancer chemotherapy. This Special Issue aims to gather relevant and innovative research advances in the field of development of new anticancer compound and drug development. We invite all researchers working in this field to contribute original articles which present the results of their research activity. Both original research articles and reviews are welcome for submission.

### Guest Editors

Prof. Dr. Pietro Campiglia


Department of Pharmacy, University of Salerno, Fisciano, Italy

Dr. Veronica Di Sarno

Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy

### Deadline for manuscript submissions

closed (1 July 2023)



## Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.2  
CiteScore 7.4  
Indexed in PubMed




[mdpi.com/si/116079](https://mdpi.com/si/116079)

*Molecules*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.2  
CiteScore 7.4  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2024).